Simple Summary Upon BNT162b2 mRNA vaccinations, multiple myeloma (MM) and
Waldenstrom's macroglobulinemia (WM) patient cohorts on active therapy affecting B cell …

Patients with multiple myeloma (MM) mount suboptimal neutralizing antibodies (nAb)
following 2 doses of SARS-CoV-2 mRNA vaccines. Currently, circulating SARS-CoV-2 …

Vaccination against SARS-CoV-2 is considered as the most important preventive strategy
against COVID-19, but its efficacy in patients with hematological malignancies is largely …

The rapid development of safe and effective vaccines is imperative to attenuate the impact of
the COVID-19 pandemic. 1 Patients with multiple myeloma (MM) are at increased risk of …

Immunocompromised individuals including patients with hematological malignancies
constitute a population at high risk of developing severe disease upon SARS-CoV-2 …

Patients with multiple myeloma (MM) have a suboptimal antibody response following
vaccination against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) and …

COVID-19 vaccination leads to a less intense humoral response in patients with multiple
myeloma (MM) compared with healthy individuals, whereas the SARS-CoV-2-specific …

Patients with multiple myeloma (MM) are a heterogenous, immunocompromised group with
increased risk for COVID-19 morbidity and mortality but impaired responses to primary …

Despite the efficacy of COVID-19 vaccines in healthy individuals, multiple myeloma (MM)
patients are immunocompromised and mount suboptimal humoral and cellular responses …

Patients with multiple myeloma (MM) are at an increased risk for infection because of their
immunocompromised state, old age, and comorbidities. 1 Coronavirus disease 2019 …